Science ❯ Psychology

Psychedelics

Therapeutic Effects Research Therapeutic Use Clinical Trials Therapeutic Applications Drug Development Psilocybin Ibogaine Drug Research Substance Use Disorders

Single High Dose of Psilocybin Linked to Short-Term Brain Changes and Improved Well-Being

A small controlled trial ties the drug’s acute brain effects to later gains in reported well-being.

Single High Dose of Psilocybin Tied to Lasting Brain Changes and Month-Later Well-Being

Trump Order to Speed Psychedelic Therapies Sends Compass Pathways to 52-Week High

New Analysis Finds Psychedelic Therapy Matches Antidepressants for Major Depression

German Psilocybin Trial in Treatment-Resistant Depression Shows Modest Gains, Misses Main Goal

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Single IV Dose of DMT Shows Rapid, Lasting Antidepressant Effects in Small Trial

Bryan Johnson Takes High-Dose Psilocybin in Public Self-Experiment on Aging

Single Psilocybin Dose Plus Mindfulness Eases Depression for Frontline Clinicians in Randomized Trial

New Zealand Approves Medical Use of Psilocybin for Treatment-Resistant Depression

Single Psilocybin Dose Offers Long-Term Relief for Cancer-Related Depression

Single Psilocybin Dose Delivers Two-Year Relief From Depression and Anxiety in Cancer Patients

Global Experts Release ReSPCT Guidelines to Standardize Psychedelic Trial Reporting

VA Launches First Psychedelic Therapy Study in Over 50 Years to Address PTSD in Veterans

Psilocybin Therapy Shows Promise for Millions with Depression

FDA Declines MDMA for PTSD Treatment, Requests Further Trials